e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Adherence in bronchiectasis (BQ) and concordance between multidimensional scales in a cohort of patients colonized by Pseudomonas aeruginosa (PsA).
E. Garcia Cortacero (Granada, Spain)
Source:
International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies
Session:
Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies
Session type:
Thematic Poster
Number:
4070
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Garcia Cortacero (Granada, Spain). Adherence in bronchiectasis (BQ) and concordance between multidimensional scales in a cohort of patients colonized by Pseudomonas aeruginosa (PsA).. 4070
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA).
Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Year: 2017
Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Year: 2018
DNA fingerprinting of
Pseudomonas aeruginosa (Pa)
in cystic fibrosis patients: risk assessment of cross-colonisation in a CF revalidation centre
Source: Eur Respir J 2002; 20: Suppl. 38, 208s
Year: 2002
Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA)
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Year: 2018
Serial measures of airway function in infants & preschoolers with cystic fibrosis (CF) according to
pseudomonas aeruginosa
(PsA) status
Source: Eur Respir J 2007; 30: Suppl. 51, 449s
Year: 2007
Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline
Source: International Congress 2017 – Update on community acquired pneumonia
Year: 2017
Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study
Source: Eur Respir J 2009; 34: 1072-1078
Year: 2009
A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic
pseudomonas aeruginosa
(PA) infection for pharmacokinetic and therapeutic equivalence
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD.
Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond
Year: 2020
Assessment of health-related quality of life in patients with bronchiectasis colonized by Pseudomonas aeruginosa
Source: Virtual Congress 2021 – Bronchiectasis and pleural infection
Year: 2021
Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients
Source: Eur Respir J 2006 Oct 01;28(4):740-747
Year: 2006
Influence of biofim on the bronchial microbiome in COPD patients colonized or infected by pseudomonas aeruginosa
Source: International Congress 2015 – Advances from translational research in respiratory infections
Year: 2015
Change in the susceptibility pattern of
Streptococcus pneumoniae
(SP) and risk factors (RF) for antibiotic resistance (AR) in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2003; 22: Suppl. 45, 546s
Year: 2003
Newly acquired
pseudomonas aeruginosa
(P.a.) in Belgian CF-patients: does the patients‘ P.a. genotype correlate with environmental genotypes?
Source: Annual Congress 2004 - Cystic fibrosis in the 21
st
century: cutting edge investigations, taxing problems
Year: 2004
Pseudomonas aeruginosa
colonisation in patients without bronchiectasis
Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura
Year: 2014
An experience of moxifloxacin (MOX) use in therapy of nosocomial pneumonia (NP) in patients who hadn‘t risk factors to be infected by
Pseudomonas aeruginosa
Source: Eur Respir J 2005; 26: Suppl. 49, 187s
Year: 2005
A randomised placebo-controlled dose finding study of tobramycin inhalation powder (TIP) in patients with bronchiectasis (BE) and pulmonary P. aeruginosa Pa) infection (iBEST-1)
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Year: 2018
Colonisation in stable patients with COPD: results of an Italian epidemiological study (PRIME study)
Source: Annual Congress 2005 - Acute and chronic infections in COPD
Year: 2005
Lung function, symptoms and inflammatory biomarkers in patients with bronchiectasis (brx) with and without chronic pseudomonas aeruginosa (psa) colonisation
Source: Annual Congress 2009 - Translational research/biomarkers
Year: 2009
Prevalence of relevant multi-drug resistant (MDR) pathogens in a bronchiectasis (BE) cohort.
Source: International Congress 2019 – Complex respiratory infections in clinical practice
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept